Literature DB >> 25550848

Correlation of EGFR mutation and histological subtype according to the IASLC/ATS/ERS classification of lung adenocarcinoma.

Zhen Chen1, Xiaoyan Liu1, Jing Zhao1, Hanjin Yang1, Xiaodong Teng1.   

Abstract

OBJECTIVE: To evaluate the correlation of EGFR mutation and histological subtypes of lung adenocarcinoma based on the IASLC/ATS/ERS classification.
METHODS: EGFR exons 18-21 of 206 resected lung adenocarcinoma specimens were analyzed with pyrosequecing, then the differences between histological subtypes and EGFR mutation were compared.
RESULTS: EGFR mutation was detected in 123 specmens, most of which were papillary and acinar predominant adenocarcinoma. EGFR mutation rate of the specimens with papillary, acinar or lepidic component was higher than without these components (P < 0.05), and with solid or mucinous component was lower than that without the component (P < 0.05). EGFR mutation in solid predominant mixed other subtypes was more commonly found than that of pure solid component (P=0.018).
CONCLUSIONS: The presence of well-differentiated components in lung adenocarcinoma, such as lepidic, papillary and acinar, indicates a higher EGFR mutation rate, while the solid and mucinous component indicate a lower EGFR mutation rate. There is heterogeneity of EGFR mutation in lung adenocarcinoma.

Entities:  

Keywords:  Lung neoplasms; adenocarcinoma; epidermal growth factor; receptor

Mesh:

Substances:

Year:  2014        PMID: 25550848      PMCID: PMC4270542     

Source DB:  PubMed          Journal:  Int J Clin Exp Pathol        ISSN: 1936-2625


  18 in total

Review 1.  Seventh edition of the cancer staging manual and stage grouping of lung cancer: quick reference chart and diagrams.

Authors:  Omar Lababede; Moulay Meziane; Thomas Rice
Journal:  Chest       Date:  2011-01       Impact factor: 9.410

2.  EGFR mutation is specific for terminal respiratory unit type adenocarcinoma.

Authors:  Yasushi Yatabe; Takayuki Kosaka; Takashi Takahashi; Tetsuya Mitsudomi
Journal:  Am J Surg Pathol       Date:  2005-05       Impact factor: 6.394

Review 3.  International association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinoma.

Authors:  William D Travis; Elisabeth Brambilla; Masayuki Noguchi; Andrew G Nicholson; Kim R Geisinger; Yasushi Yatabe; David G Beer; Charles A Powell; Gregory J Riely; Paul E Van Schil; Kavita Garg; John H M Austin; Hisao Asamura; Valerie W Rusch; Fred R Hirsch; Giorgio Scagliotti; Tetsuya Mitsudomi; Rudolf M Huber; Yuichi Ishikawa; James Jett; Montserrat Sanchez-Cespedes; Jean-Paul Sculier; Takashi Takahashi; Masahiro Tsuboi; Johan Vansteenkiste; Ignacio Wistuba; Pan-Chyr Yang; Denise Aberle; Christian Brambilla; Douglas Flieder; Wilbur Franklin; Adi Gazdar; Michael Gould; Philip Hasleton; Douglas Henderson; Bruce Johnson; David Johnson; Keith Kerr; Keiko Kuriyama; Jin Soo Lee; Vincent A Miller; Iver Petersen; Victor Roggli; Rafael Rosell; Nagahiro Saijo; Erik Thunnissen; Ming Tsao; David Yankelewitz
Journal:  J Thorac Oncol       Date:  2011-02       Impact factor: 15.609

4.  Mutations of the epidermal growth factor receptor gene in lung cancer: biological and clinical implications.

Authors:  Takayuki Kosaka; Yasushi Yatabe; Hideki Endoh; Hiroyuki Kuwano; Takashi Takahashi; Tetsuya Mitsudomi
Journal:  Cancer Res       Date:  2004-12-15       Impact factor: 12.701

5.  Histopathological features and prognostic significance of the micropapillary pattern in lung adenocarcinoma.

Authors:  Kazunori Kamiya; Yuichiro Hayashi; Junya Douguchi; Akinori Hashiguchi; Taketo Yamada; Yotaro Izumi; Masazumi Watanabe; Masafumi Kawamura; Hirohisa Horinouchi; Naoki Shimada; Koichi Kobayashi; Michiie Sakamoto
Journal:  Mod Pathol       Date:  2008-05-30       Impact factor: 7.842

Review 6.  The predictive value of epidermal growth factor receptor tests in patients with pulmonary adenocarcinoma: review of current "best evidence" with meta-analysis.

Authors:  Ruta Gupta; Aditi M Dastane; Robert McKenna; Alberto M Marchevsky
Journal:  Hum Pathol       Date:  2008-10-30       Impact factor: 3.466

7.  Bronchioloalveolar pathologic subtype and smoking history predict sensitivity to gefitinib in advanced non-small-cell lung cancer.

Authors:  Vincent A Miller; Mark G Kris; Neelam Shah; Jyoti Patel; Christopher Azzoli; Jorge Gomez; Lee M Krug; William Pao; Naiyer Rizvi; Barbara Pizzo; Leslie Tyson; Ennapadam Venkatraman; Leah Ben-Porat; Natalie Memoli; Maureen Zakowski; Valerie Rusch; Robert T Heelan
Journal:  J Clin Oncol       Date:  2004-03-15       Impact factor: 44.544

8.  Lung adenocarcinoma: modification of the 2004 WHO mixed subtype to include the major histologic subtype suggests correlations between papillary and micropapillary adenocarcinoma subtypes, EGFR mutations and gene expression analysis.

Authors:  Noriko Motoi; Janos Szoke; Gregory J Riely; Venkatraman E Seshan; Mark G Kris; Valerie W Rusch; William L Gerald; William D Travis
Journal:  Am J Surg Pathol       Date:  2008-06       Impact factor: 6.394

9.  Genotype-phenotype correlation in Chinese patients with pulmonary mixed type adenocarcinoma: Relationship between histologic subtypes, TITF-1/SP-A expressions and EGFR mutations.

Authors:  Xing-Ya Li; Yan-Qiu Zhao; Rui-Qing Liu; Jian-Bo Zhang; Jie Ma; Li-Juan Chen; Xiu-Feng Hu
Journal:  Pathol Res Pract       Date:  2013-12-05       Impact factor: 3.250

10.  Mutations in the epidermal growth factor receptor gene are linked to smoking-independent, lung adenocarcinoma.

Authors:  M Sonobe; T Manabe; H Wada; F Tanaka
Journal:  Br J Cancer       Date:  2005-08-08       Impact factor: 7.640

View more
  16 in total

1.  A comprehensive evaluation of clinicopathologic characteristics, molecular features and prognosis in lung adenocarcinoma with solid component.

Authors:  Jing Li; Wenjie You; Difan Zheng; Bei Yan; Xiao Ma; Yunjian Pan; Yang Zhang; Yuan Li; Xuxia Shen; Xinghua Cheng; Yihua Sun; Haiquan Chen
Journal:  J Cancer Res Clin Oncol       Date:  2018-01-24       Impact factor: 4.553

2.  Clinical usefulness of the 3-tier classification according to the proportion of morphological patterns for patients with pathological stage I invasive lung adenocarcinoma.

Authors:  Junichiro Osawa; Yoshihisa Shimada; Sachio Maehara; Masaru Hagiwara; Masatoshi Kakihana; Naohiro Kajiwara; Tatsuo Ohira; Jun Matsubayashi; Norihiko Ikeda
Journal:  Gen Thorac Cardiovasc Surg       Date:  2021-01-01

3.  ALK rearrangement in specific subtypes of lung adenocarcinoma: immunophenotypic and morphological features.

Authors:  Luciana Possidente; Matteo Landriscina; Giuseppe Patitucci; Ludovica Borgia; Vittoria Lalinga; Giulia Vita
Journal:  Med Oncol       Date:  2017-03-31       Impact factor: 3.064

4.  Primary mucinous adenocarcinoma of the lung: A case report and review of the literature.

Authors:  Yan Liu; He-Long Zhang; Jia-Zhuan Mei; Yan-Wei Guo; Rui-Jun Li; Si-Dong Wei; Fu Tian; Lu Yang; Hui Wang
Journal:  Oncol Lett       Date:  2017-07-20       Impact factor: 2.967

5.  Prognostic value of epidermal growth factor receptor mutations and histologic subtypes with lung adenocarcinoma.

Authors:  Nozomu Motono; Aika Funasaki; Atsushi Sekimura; Katsuo Usuda; Hidetaka Uramoto
Journal:  Med Oncol       Date:  2018-01-31       Impact factor: 3.064

6.  Evaluation of epidermal growth factor receptor mutations and thyroid transcription factor-1 status in Turkish non-small cell lung carcinoma patients: A study of 600 cases from a single center.

Authors:  Malahat Musayeva; Serpil Dizbay Sak; Hilal Özakıncı; Şenay Boyacıgil; Öznur Coşkun
Journal:  Turk Gogus Kalp Damar Cerrahisi Derg       Date:  2020-01-23       Impact factor: 0.332

7.  miR-198 targets SHMT1 to inhibit cell proliferation and enhance cell apoptosis in lung adenocarcinoma.

Authors:  Shujun Wu; Guojun Zhang; Ping Li; Shanshan Chen; Furui Zhang; Juan Li; Chenyang Jiang; Xiaonan Chen; Yuanyuan Wang; Yuwen Du; Qianqian Sun; Guoqiang Zhao
Journal:  Tumour Biol       Date:  2015-11-09

8.  Clinicopathological, Radiological, and Molecular Features of Primary Lung Adenocarcinoma with Morule-Like Components.

Authors:  Li-Li Wang; Li Ding; Peng Zhao; Jing-Jing Guan; Xiao-Bin Ji; Xiao-Li Zhou; Shi-Hong Shao; Yu-Wei Zou; Wei-Wei Fu; Dong-Liang Lin
Journal:  Dis Markers       Date:  2021-06-12       Impact factor: 3.434

9.  Identification of lung adenocarcinoma mutation status based on histologic subtype: Retrospective analysis of 269 patients.

Authors:  Fangliang Lu; Shaolei Li; Bin Dong; Shanyuan Zhang; Chao Lv; Yue Yang
Journal:  Thorac Cancer       Date:  2015-05-26       Impact factor: 3.500

10.  Relationship of epidermal growth factor receptor activating mutations with histologic subtyping according to International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society 2011 adenocarcinoma classification and their impact on overall survival.

Authors:  Venkata Nagarjuna Maturu; Navneet Singh; Amanjit Bal; Nalini Gupta; Ashim Das; Digambar Behera
Journal:  Lung India       Date:  2016 May-Jun
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.